People channel feed

UK en­vi­ron­men­tal ini­tia­tive taps a big name in ad­ver­tis­ing to lead US ef­forts

3 years ago

Car­olyn Bertozzi, re­peat biotech founder and launch­er of a field, shares in chem­istry No­bel win

3 years ago

Pen­ny stock, Mer­ck part­ner lays off 45% of staff to reach PhII read­out by ear­ly 2023

3 years ago
R&D

Jeff Mar­raz­zo has found a buzzy new biotech cause to cham­pi­on. And once again, he's all in

3 years ago
Bioregnum

Fa­ther starts lab af­ter in­tel­lec­tu­al prop­er­ty is­sues stymie rare dis­ease drug de­vel­op­ment

3 years ago
Pharma
In Focus

Roche hires new di­ag­nos­tics chief from with­in, ahead of C-suite shake-up

3 years ago
Pharma

George Church, Wyss sci­en­tists and North­pond chal­lenge con­ven­tion­al RNA man­u­fac­tur­ing with new biotech

3 years ago
Financing
Cell/Gene Tx

Some­one old, some­one new: Mod­er­na pro­motes CTO, raids No­var­tis for re­place­ment amid pipeline push

3 years ago
Pharma

In sur­vival mode, Ex­i­cure cuts to the bone — paus­ing all R&D and chop­ping head­count by 66%

3 years ago
R&D

FDA's top gener­ic drug leader puts in her two weeks as GDU­FA III looms

3 years ago
FDA+

Ru­bik's Cube still not solved at Mereo as ac­tivist in­vestor re­jects biotech's of­fer for board seats

3 years ago

With con­sumer health be­hind it, GSK taps As­traZeneca vet Julie Brown as CFO for R&D-fo­cused fu­ture

3 years ago

WPP taps Organon chief com­mu­ni­ca­tions of­fi­cer Wendy Lund for new health and well­ness client role

3 years ago
Pharma
Marketing

Months af­ter launch­ing with lofty goal, Flag­ship start­up stream­lines ops, chops head­count

3 years ago

As Gami­da Cell eyes its first cell ther­a­py ap­proval, Ju­lian Adams is head­ing out

3 years ago

Still car­ry­ing the bud­get axe, Kåre Schultz is wrap­ping up his stint at Te­va, promis­ing to start pay­ing opi­oid set­tle­ment

3 years ago
Pharma

Pal­isade Bio is the lat­est to re­struc­ture, hun­ker­ing down on its lead pro­gram

3 years ago
R&D

Scoop: Ab­b­Vie, Bris­tol My­ers bring out the bud­get axe, out­lin­ing plans to lay off more than 350 West Coast em­ploy­ees

3 years ago
Pharma

Trou­bled times: With its back against the wall, lit­tle Tenax sends out an SOS while IMV takes out the bud­get axe, chops staff

3 years ago
Pharma

Ru­bius re­sorts to lay­offs and aban­dons its lead pro­grams as its sur­vival strat­e­gy

3 years ago
R&D
Cell/Gene Tx

In af­ter­math of lead drug im­plo­sion, Ob­sE­va's re­struc­tur­ing claims 70% of its staffers — reach­ing in­to the C-suite

3 years ago

Ver­i­ly hooks $1B round amid C-suite shuf­fle

3 years ago
Financing
Pharma

Biden turns to biotech for his in­au­gur­al ARPA-H di­rec­tor

3 years ago
FDA+

Here's your in­vi­ta­tion to this year's End­points 11 awards. Let's cel­e­brate the best of biotech to­geth­er

3 years ago
First page Previous page 37383940414243 Next page Last page
A service from the Financial Times